1. Report Introduction 2. Cone-Rod Dystrophies Market Overview at a Glance 2.1. Market Share Distribution of Cone-Rod Dystrophies in 2018 2.2. Market Share Distribution of Cone-Rod Dystrophies in 2028 3. Disease Background and Overview: Cone-Rod Dystrophies 3.1. Introduction 3.2. Symptoms 3.3. Etiology 3.4. Risk Factors 3.5. Pathophysiology 3.6. Diagnosis 3.7. Treatment 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Prevalent/ Incident Patient Population of Cone-Rod Dystrophies in 7MM 4.3. Total Prevalent Patient Population of Cone-Rod Dystrophies in 7MM – By Countries 5. Epidemiology of Cone-Rod Dystrophies by Countries 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Prevalent/Incident Cases of the Cone-Rod Dystrophies 5.1.3. Sub-Type Specific cases of the Cone-Rod Dystrophies *Indication Specific 5.1.4. Sex- Specific Cases of the Cone-Rod Dystrophies*Indication Specific 5.1.5. Diagnosed Cases of the Cone-Rod Dystrophies 5.1.6. Treatable Cases of the Cone-Rod Dystrophies 5.2. EU5 5.3. Assumptions and Rationale 5.4. Germany 5.4.1. Assumptions and Rationale 5.4.2. Prevalent/Incident Cases of the Cone-Rod Dystrophies 5.4.3. Sub-Type Specific cases of the Cone-Rod Dystrophies* 5.4.4. Sex- Specific Cases of the Cone-Rod Dystrophies* 5.4.5. Diagnosed Cases of the Cone-Rod Dystrophies 5.4.6. Treatable Cases of the Cone-Rod Dystrophies 5.5. France 5.5.1. Assumptions and Rationale 5.5.2. Prevalent/Incident Cases of the Cone-Rod Dystrophies 5.5.3. Sub-Type Specific cases of the Cone-Rod Dystrophies* 5.5.4. Sex- Specific Cases of the Cone-Rod Dystrophies* 5.5.5. Diagnosed Cases of the Cone-Rod Dystrophies 5.5.6. Treatable Cases of the Cone-Rod Dystrophies 5.6. Italy 5.6.1. Assumptions and Rationale 5.6.2. Prevalent/Incident Cases of the Cone-Rod Dystrophies 5.6.3. Sub-Type Specific cases of the Cone-Rod Dystrophies* 5.6.4. Sex- Specific Cases of the Cone-Rod Dystrophies* 5.6.5. Diagnosed Cases of the Cone-Rod Dystrophies 5.6.6. Treatable Cases of the Cone-Rod Dystrophies 5.7. Spain 5.7.1. Assumptions and Rationale 5.7.2. Prevalent/Incident Cases of the Cone-Rod Dystrophies 5.7.3. Sub-Type Specific cases of the Cone-Rod Dystrophies* 5.7.4. Sex- Specific Cases of the Cone-Rod Dystrophies* 5.7.5. Diagnosed Cases of the Cone-Rod Dystrophies 5.7.6. Treatable Cases of the Cone-Rod Dystrophies 5.8. United Kingdom 5.8.1. Assumptions and Rationale 5.8.2. Prevalent/Incident Cases of the Cone-Rod Dystrophies 5.8.3. Sub-Type Specific cases of the Cone-Rod Dystrophies* 5.8.4. Sex- Specific Cases of the Cone-Rod Dystrophies* 5.8.5. Diagnosed Cases of the Cone-Rod Dystrophies 5.8.6. Treatable Cases of the Cone-Rod Dystrophies 5.9. Japan 5.9.1. Assumptions and Rationale 5.9.2. Prevalent/Incident Cases of the Cone-Rod Dystrophies 5.9.3. Sub-Type Specific cases of the Cone-Rod Dystrophies* 5.9.4. Sex- Specific Cases of the Cone-Rod Dystrophies* 5.9.5. Diagnosed Cases of the Cone-Rod Dystrophies 5.9.6. Treatable Cases of the Cone-Rod Dystrophies 6. Current Treatment & Medical practices 6.1. Treatment Algorithm 6.2. Treatment Guidelines 7. Unmet Needs of the Cone-Rod Dystrophies 8. Marketed Therapies 8.1. Drug A: Company 1 8.1.1. Drug Description 8.1.2. Mechanism of Action 8.1.3. Regulatory Milestones 8.1.4. Advantages & Disadvantages 8.1.5. Product Profile 8.2. Drug B: Company 2 8.2.1. Drug Description 8.2.2. Mechanism of Action 8.2.3. Regulatory Milestones 8.2.4. Advantages & Disadvantages 8.2.5. Product Profile 9. Pipeline Therapies – At a glance 10. Key Cross Competition 11. Emerging Therapies for Cone-Rod Dystrophies 11.1. Drug C: Company 3 11.1.1. Drug Description 11.1.2. Clinical Trials Details 11.1.3. Safety and Efficacy Profile 11.1.4. Advantages & Disadvantages 11.1.5. Pipeline Development Activities 11.1.6. Product Profile 11.2. Drug D: Company 4 11.2.1. Drug Description 11.2.2. Clinical Trials Details 11.2.3. Safety and Efficacy Profile 11.2.4. Advantages & Disadvantages 11.2.5. Pipeline Development Activities 11.2.6. Product Profile 12. Cone-Rod Dystrophies: 7MM Market Analysis 12.1. 7MM Market Size of Cone-Rod Dystrophies 12.2. 7MM Percentage Share of drugs marketed for Cone-Rod Dystrophies 12.3. 7MM Market Sales of Cone-Rod Dystrophies by Products 13. Cone-Rod Dystrophies: Country-Wise Market Analysis 13.1. United States 13.1.1. Market Size of Cone-Rod Dystrophies in United States 13.1.2. Percentage Share of drugs marketed for Cone-Rod Dystrophies in United States 13.1.3. Market Sales of Cone-Rod Dystrophies by Products in United States 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2. EU-5 13.2.1. Germany 13.2.1.1. Market Size of Cone-Rod Dystrophies in Germany 13.2.1.2. Percentage Share of drugs marketed for Cone-Rod Dystrophies in Germany 13.2.1.3. Market Sales of Cone-Rod Dystrophies by Products in Germany 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.2. France 13.2.2.1. Market Size of Cone-Rod Dystrophies in France 13.2.2.2. Percentage Share of drugs marketed for Cone-Rod Dystrophies in France 13.2.2.3. Market Sales of Cone-Rod Dystrophies by Products in France 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.3. Italy 13.2.3.1. Market Size of Cone-Rod Dystrophies in Italy 13.2.3.2. Percentage Share of drugs marketed for Cone-Rod Dystrophies in Italy 13.2.3.3. Market Sales of Cone-Rod Dystrophies by Products in Italy 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.4. Spain 13.2.4.1. Market Size of Cone-Rod Dystrophies in Spain 13.2.4.2. Percentage Share of drugs marketed for Cone-Rod Dystrophies in Spain 13.2.4.3. Market Sales of Cone-Rod Dystrophies by Products in Spain 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market 13.2.5. United Kingdom 13.2.5.1. Market Size of Cone-Rod Dystrophies in United Kingdom 13.2.5.2. Percentage Share of drugs marketed for Cone-Rod Dystrophies in United Kingdom 13.2.5.3. Market Sales of Cone-Rod Dystrophies by Products in United Kingdom 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market 13.3. Japan 13.3.1. Market Size of Cone-Rod Dystrophies in Japan 13.3.2. Percentage Share of drugs marketed for Cone-Rod Dystrophies in Japan 13.3.3. Market Sales of Cone-Rod Dystrophies by Products in Japan 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market 14. Market Drivers 15. Market Barriers 16. Appendix 17. Report Methodology 17.1. Sources 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight

Table 1: Total Prevalent/Incident Cases of the Cone-Rod Dystrophies in 7MM Table 2: Total Prevalent/Incident Cases of the Cone-Rod Dystrophies in 7MM by Countries Table 3: Prevalent/Incident Cases of the Cone-Rod Dystrophies in United States (2017-2028) Table 4: Sub-Type Specific cases of the Cone-Rod Dystrophies in United States (2017-2028) Table 5: Sex- Specific Cases of the Cone-Rod Dystrophies in United States (2017-2028) Table 6: Diagnosed Cases of the Cone-Rod Dystrophies in United States (2017-2028) Table 7: Treatable Cases of the Cone-Rod Dystrophies in United States (2017-2028) Table 8: Prevalent/Incident Cases of the Cone-Rod Dystrophies in Germany (2017-2028) Table 9: Sub-Type Specific cases of the Cone-Rod Dystrophies in Germany (2017-2028) Table 10: Sex- Specific Cases of the Cone-Rod Dystrophies in Germany (2017-2028) Table 11: Diagnosed Cases of the Cone-Rod Dystrophies in Germany (2017-2028) Table 12: Treatable Cases of the Cone-Rod Dystrophies in Germany (2017-2028) Table 13: Prevalent/Incident Cases of the Cone-Rod Dystrophies in France (2017-2028) Table 14: Sub-Type Specific cases of the Cone-Rod Dystrophies in France (2017-2028) Table 15: Sex- Specific Cases of the Cone-Rod Dystrophies in France (2017-2028) Table 16: Diagnosed Cases of the Cone-Rod Dystrophies in France (2017-2028) Table 17: Treatable Cases of the Cone-Rod Dystrophies in France (2017-2028) Table 18: Prevalent/Incident Cases of the Cone-Rod Dystrophies in Italy (2017-2028) Table 19: Sub-Type Specific cases of the Cone-Rod Dystrophies in Italy (2017-2028) Table 20: Sex- Specific Cases of the Cone-Rod Dystrophies in Italy (2017-2028) Table 21: Diagnosed Cases of the Cone-Rod Dystrophies in Italy (2017-2028) Table 22: Treatable Cases of the Cone-Rod Dystrophies in Italy (2017-2028) Table 23: Prevalent/Incident Cases of the Cone-Rod Dystrophies in Spain (2017-2028) Table 24: Sub-Type Specific cases of the Cone-Rod Dystrophies in Spain (2017-2028) Table 25: Sex- Specific Cases of the Cone-Rod Dystrophies in Spain (2017-2028) Table 26: Diagnosed Cases of the Cone-Rod Dystrophies in Spain (2017-2028) Table 27: Treatable Cases of the Cone-Rod Dystrophies in Spain (2017-2028) Table 28: Prevalent/Incident Cases of the Cone-Rod Dystrophies in UK (2017-2028) Table 29: Sub-Type Specific cases of the Cone-Rod Dystrophies in UK (2017-2028) Table 30: Sex- Specific Cases of the Cone-Rod Dystrophies in UK (2017-2028) Table 31: Diagnosed Cases of the Cone-Rod Dystrophies in UK (2017-2028) Table 32: Treatable Cases of the Cone-Rod Dystrophies in UK (2017-2028) Table 33: Prevalent/Incident Cases of the Cone-Rod Dystrophies in Japan (2017-2028) Table 34: Sub-Type Specific cases of the Cone-Rod Dystrophies in Japan (2017-2028) Table 35: Sex- Specific Cases of the Cone-Rod Dystrophies in Japan (2017-2028) Table 36: Diagnosed Cases of the Cone-Rod Dystrophies in Japan (2017-2028) Table 37: Treatable Cases of the Cone-Rod Dystrophies in Japan (2017-2028) Table 38: Marketed Therapies Table 39: Emerging Therapies Table 40: Key Cross Competition Table 41:7MM- Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Table 42:7MM- Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 43:7MM- Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 44: United States-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Table 45: United States-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 46: United States-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 47: Germany-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Table 48: Germany-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 49: Germany-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 50: France-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Table 51: France-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 52: France-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 53: Italy-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Table 54: Italy-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 55: Italy-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 56: Spain-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Table 57: Spain-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 58: Spain-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 59:UK-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Table 60:UK-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 61:UK-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 62: Japan-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Table 63: Japan-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Table 64: Japan-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 1: Total Prevalent/Incident Cases of the Cone-Rod Dystrophies in 7MM Figure 2: Total Prevalent/Incident Cases of the Cone-Rod Dystrophies in 7MM by Countries Figure 3: Prevalent/Incident Cases of the Cone-Rod Dystrophies in United States (2017-2028) Figure 4: Sub-Type Specific cases of the Cone-Rod Dystrophies in United States (2017-2028) Figure 5: Sex- Specific Cases of the Cone-Rod Dystrophies in United States (2017-2028) Figure 6: Diagnosed Cases of the Cone-Rod Dystrophies in United States (2017-2028) Figure 7: Treatable Cases of the Cone-Rod Dystrophies in United States (2017-2028) Figure 8: Prevalent/Incident Cases of the Cone-Rod Dystrophies in Germany (2017-2028) Figure 9: Sub-Type Specific cases of the Cone-Rod Dystrophies in Germany (2017-2028) Figure 10: Sex- Specific Cases of the Cone-Rod Dystrophies in Germany (2017-2028) Figure 11: Diagnosed Cases of the Cone-Rod Dystrophies in Germany (2017-2028) Figure 12: Treatable Cases of the Cone-Rod Dystrophies in Germany (2017-2028) Figure 13: Prevalent/Incident Cases of the Cone-Rod Dystrophies in France (2017-2028) Figure 14: Sub-Type Specific cases of the Cone-Rod Dystrophies in France (2017-2028) Figure 15: Sex- Specific Cases of the Cone-Rod Dystrophies in France (2017-2028) Figure 16: Diagnosed Cases of the Cone-Rod Dystrophies in France (2017-2028) Figure 17: Treatable Cases of the Cone-Rod Dystrophies in France (2017-2028) Figure 18: Prevalent/Incident Cases of the Cone-Rod Dystrophies in Italy (2017-2028) Figure 19: Sub-Type Specific cases of the Cone-Rod Dystrophies in Italy (2017-2028) Figure 20: Sex- Specific Cases of the Cone-Rod Dystrophies in Italy (2017-2028) Figure 21: Diagnosed Cases of the Cone-Rod Dystrophies in Italy (2017-2028) Figure 22: Treatable Cases of the Cone-Rod Dystrophies in Italy (2017-2028) Figure 23: Prevalent/Incident Cases of the Cone-Rod Dystrophies in Spain (2017-2028) Figure 24: Sub-Type Specific cases of the Cone-Rod Dystrophies in Spain (2017-2028) Figure 25: Sex- Specific Cases of the Cone-Rod Dystrophies in Spain (2017-2028) Figure 26: Diagnosed Cases of the Cone-Rod Dystrophies in Spain (2017-2028) Figure 27: Treatable Cases of the Cone-Rod Dystrophies in Spain (2017-2028) Figure 28: Prevalent/Incident Cases of the Cone-Rod Dystrophies in UK (2017-2028) Figure 29: Sub-Type Specific cases of the Cone-Rod Dystrophies in UK (2017-2028) Figure 30: Sex- Specific Cases of the Cone-Rod Dystrophies in UK (2017-2028) Figure 31: Diagnosed Cases of the Cone-Rod Dystrophies in UK (2017-2028) Figure 32: Treatable Cases of the Cone-Rod Dystrophies in UK (2017-2028) Figure 33: Prevalent/Incident Cases of the Cone-Rod Dystrophies in Japan (2017-2028) Figure 34: Sub-Type Specific cases of the Cone-Rod Dystrophies in Japan (2017-2028) Figure 35: Sex- Specific Cases of the Cone-Rod Dystrophies in Japan (2017-2028) Figure 36: Diagnosed Cases of the Cone-Rod Dystrophies in Japan (2017-2028) Figure 37: Treatable Cases of the Cone-Rod Dystrophies in Japan (2017-2028) Figure 38: Marketed Therapies Figure 39: Emerging Therapies Figure 40: Key Cross Competition Figure 41:7MM- Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Figure 42:7MM- Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 43:7MM- Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 44: United States-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Figure 45: United States-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 46: United States-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 47: Germany-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Figure 48: Germany-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 49: Germany-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 50: France-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Figure 51: France-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 52: France-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 53: Italy-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Figure 54: Italy-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 55: Italy-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 56: Spain-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Figure 57: Spain-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 58: Spain-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 59:UK-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Figure 60:UK-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 61:UK-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 62: Japan-Market Size of Cone-Rod Dystrophies in USD MM (2017-2028) Figure 63: Japan-Market Share Cone-Rod Dystrophies by Therapies in USD MM (2017-2028) Figure 64: Japan-Market Sales of Cone-Rod Dystrophies by Therapies in USD MM (2017-2028)